SCHEMBL5011965

SCHEMBL5011965

COc1cccc(OC)c1C1=C2C=CC(=N2)C(c2ccccc2)=C2C=CC(=N2)C(c2ccccc2)=C2C=CC(=N2)C(c2ccccc2)=C2C=CC1=N2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FABP4 P15090 2/20 0.42
▸ FABP3 P05413 1/20 0.42
▸ FABP5 Q01469 1/20 0.42
▸ FGFR1 P11362 1/20 0.40
▸ SRC P12931 1/20 0.40
▸ FGFR2 P21802 1/20 0.40
▸ FGFR4 P22455 1/20 0.40
▸ FGFR3 P22607 1/20 0.40
▸ KMT2A Q03164 4/20 0.37
▸ MEN1 O00255 3/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ CA12 O43570 1/20 0.35
▸ CA1 P00915 1/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA4 P22748 1/20 0.35
▸ CA7 P43166 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ CA14 Q9ULX7 1/20 0.35
▸ PDE4B Q07343 1/20 0.35
▸ TOP1 P11387 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5016673 1.00 FABP4 (0.42) FABP4FABP3FABP5FGFR1SRC
SCHEMBL26676737 0.91 TOP1 (0.41) KMT2AMEN1CA12CA1CA2
SCHEMBL5016486 0.82 TOP1 (0.35) CA12CA1CA2CA4CA7
SCHEMBL28180007 0.78 ALDH1A1 (0.35) KMT2AMEN1PDE4BALDH1A1KDM4E
SCHEMBL2517442 0.78 ALDH1A1 (0.35) KMT2AMEN1PDE4BALDH1A1KDM4E
SCHEMBL27979361 0.78 ALDH1A1 (0.35) KMT2AMEN1PDE4BALDH1A1KDM4E
SCHEMBL14562749 0.78 ALDH1A1 (0.35) KMT2AMEN1PDE4BALDH1A1KDM4E
SCHEMBL7996476 0.78 ALDH1A1 (0.35) KMT2AMEN1PDE4BALDH1A1KDM4E
Trimethylammonium SCHEMBL8994460 0.77 GSK3B (0.35) KMT2AMEN1PDE4BALDH1A1SMN1; SMN2
SCHEMBL5013871 0.76 KDM4E (0.38) KMT2AMEN1NPSR1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7417142-B2 Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, INC. (US) 2008-08-26 — — US disclosed
US-20060030718-A1 Cobalt-based catalysts for the cyclization of alkenes UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2006-02-09 — — US disclosed
US-20050124596-A1 Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2005-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060030718-A1 Cobalt-based catalysts for the cyclization of alkenes PPOX, HCCS, ICOSLG FABP4 4351/4885FABP3 4080/4885FABP5 3912/4885
US-20050124596-A1 Chiral porphyrins, chiral metalloporphyrins, and methods for synthesis of the same PPOX, PPIF, HMBS FABP4 3317/4885FABP3 3160/4885FABP5 2328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback